

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

NeuroSearch A/S' share capital and voting rights

On 27 November 2007, the share capital in NeuroSearch A/S was increased following subscription and issue of 2,754,579 new shares, with a nominal value of DKK 20 each.

Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers' Disclosure Obligations, it is hereby announced that at the end of November 2007, the total nominal value of NeuroSearch A/S' share capital is DKK 303,995,000, which is made up of 15,199,750 shares with a nominal value of DKK 20 each, and corresponding to 303,995,000 votes.

Asger Aamund
Chairman of the Board

Contact persons:

Flemming Pedersen, CEO

Hanne Leth Hillman, Vice President,
Director of Investor Relations & Corporate Communications

Telephone:

+45 4460 8214 or
+45 2148 0118

+45 4460 8212 or
+45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the Company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.